Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TQB2916
- Development stage
- Phase 2
- Lead developer
- Chia Tai-Tianqing Pharmaceutical Group
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TQB2916 is a humanized immunoglobulin G2 (IgG2) monoclonal antibody that acts as an agonist of the tumor necrosis factor receptor superfamily member 5 (CD40). By binding to CD40 on target cells, it activates downstream signaling pathways and stimulates anti-tumor immune responses. This includes promoting antibody-dependent cell cytotoxicity and stimulating T lymphocytes. Preclinical studies have shown that it can induce apoptosis in B-cell lymphoma cells. The drug is being developed primarily for the treatment of solid tumors, including soft tissue sarcoma and melanoma, often in combination with chemotherapy or other immunotherapies such as penpulimab (a PD-1 inhibitor). The developer is Chia Tai Tianqing Pharmaceutical Group[1][2][3].
- Other names
- Anti-CD40 monoclonal antibody (Biosion)Anti-CD40 antibody (Biosion)
02
Targets
CD40 (Cluster of differentiation 40 receptor)
Beyond the preview
Go deeper on TQB2916.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQB2916.